| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | 치환된 시클로프로판카르보알데히드의 제조 방법 | KR1019900001162 | 1990-02-01 | KR1019900012900A | 1990-09-03 | 한스-루이디쾨넬; 존그레이딩월 |
| 내용 없음 | ||||||
| 42 | 시클로 프로판 카복실산의 새로운 유도체류 | KR810001819 | 1981-05-22 | KR830006166A | 1983-09-17 | |
| 내용없음 | ||||||
| 43 | PROCESS FOR THE PREPARATION OF 3-(METHYLTHIO)PROPANAL | EP93922171.9 | 1993-09-09 | EP0703890B1 | 1999-04-07 | HSU, Yung, C.; RUEST, Dennis, A. |
| A process for the continuous preparation of 3-(methylthio)propanal. A liquid reaction medium is contacted with a gaseous acrolein feed stream in a gas/liquid contact zone. The reaction medium contains 3-(methylthio)propanal, methyl mercaptan and a catalyst for the reaction between methyl mercaptan and acrolein. The gaseous acrolein feed stream comprises acrolein vapor and non-condensable gas. Acrolein is transferred from the acrolein feed stream to the reaction medium and reacts with methyl mercaptan in that medium to produce a liquid reaction product containing 3-(methylthio)propanal. The non-condensable gas is separated from the liquid reaction product. The reaction product is divided into a product fraction and a circulating fraction, and the circulating fraction is recycled to the gas/liquid contact zone. | ||||||
| 44 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | EP96918360 | 1996-06-07 | EP0865439A4 | 1998-11-11 | HEBERT NORMAND |
| 45 | PEPTIDYLAMINODIOLS. | EP88900918 | 1987-12-22 | EP0295294A4 | 1990-04-10 | FUNG ANTHONY K L; KEMPF DALE JOHN; LULY JAY RICHARD; ROSENBERG SAUL HOWARD; PLATTNER JACOB JOHN |
| 46 | USE OF (+/-)-CIS-GAMMA-IRONE IN PERFUMERY AND NOVEL PROCESS FOR PREPARING SAME. | EP85901068 | 1985-02-21 | EP0211954A4 | 1988-12-28 | KAWANOBE TSUNEO; KOGAMI KUNIO |
| A novel perfume composition containing an effective amount of ( 9E)-cis-gamma-irone (formula (B)), which has not been heretofore applied in the field of perfumery, in perfumes or flavored articles, a method for imparting, changing or enhancing aromatic properties by compounding ( 9E)-cis-gamma-irone with perfumes or articles being flavored, and a novel process for preparing ( 9E)-cis-gamma-irone. | ||||||
| 47 | Compounds and compositions having anti-inflammatory and analgesic activity. | EP86304377 | 1986-06-09 | EP0206609A1 | 1986-12-30 | BERMAN ELIZABETH F; BUCKWALTER BRIAN; CUPPS THOMAS L; GARDNER JOSEPH H |
| Substituted phenylacetic acid amide compounds, and pharmaceutically-acceptable salts thereof, of the formula: |
||||||
| 48 | Haloalkoxy anilide derivatives of 2-(4-heterocyclic oxyphenoxy)-alkanoic acids and their use as herbicides. | EP86105675 | 1986-04-24 | EP0205821A1 | 1986-12-30 | TURNER JAMES A; ZORNER PAUL S; JACKS WENDY S; MOORE SUSAN K |
| The present invention is directed to novel substituted aniline compounds, the optically active isomers of said compounds, compositions containing said compounds, and the use of these compounds in the selective kill and control of grassy weeds in the presence of valuable crop plants especially corn plants. | ||||||
| 49 | N'-acylhydrazino-thiocarbonic-acid-o-carbamoylmethyl ester | EP84116311 | 1984-12-27 | EP0151312A3 | 1986-12-30 | MAURER, FRITZ, DR. |
| 50 | Hydrazino-thiocarbonic-acid-o-carbamoylmethyl ester | EP84116312 | 1984-12-27 | EP0148500A3 | 1986-12-30 | MAURER, FRITZ, DR. |
| 51 | NAPHTALENE AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMA CEUTICAL USES. | EP84902127 | 1984-04-27 | EP0148201A4 | 1985-09-26 | CAMPBELL HENRY FLUD; KUHLA DONALD ERNEST; STUDT WILLIAM LYON |
| 52 | ACRYLAMIDOACYLATED OLIGOMERS. | EP82903612 | 1982-10-27 | EP0091956A4 | 1984-04-24 | RASMUSSEN JERALD K; HEILMANN STEVEN M; PALENSKY FREDERICK J |
| 53 | 5-alkyl-3-alkylthiopropionthioates, process for their preparation and their use as pharmaceutical compositions | EP81101913 | 1981-03-14 | EP0036991B1 | 1983-11-16 | JACOBI, HAIREDDIN, DR.; OPITZ, WOLFGANG, DR. |
| 54 | NOVEL CRYSTALLINE FORM OF OXAMYL PROCESS FOR ITS PREPARATION AND USE OF THE SAME | US16464583 | 2017-10-20 | US20210045384A1 | 2021-02-18 | James Timothy BRISTOW |
| A crystalline form of oxamyl is provided. The crystalline form of oxamyl is of formula (I): A crystal preparation process, the analyses of the crystal through various analytical methods and using the crystalline form to prepare a stable agrochemical formulation is also provided. The use of various solvents towards the crystalline form preparation conditions is also provided. | ||||||
| 55 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | US14301569 | 2014-06-11 | US09181181B2 | 2015-11-10 | Anders Broo; Johan Gottfries; Michael Kossenjans; Li Lanna; Eva-Lotte Lindstedt-Alstermark; Kristina A. Nilsson; Bengt Ohlsson; Maria Thorstensson; Maria Boije |
| The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them. | ||||||
| 56 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | US13046288 | 2011-03-11 | US08785681B2 | 2014-07-22 | Anders Broo; Johan Gottfries; Michael Kossenjans; Li Lanna; Eva-Lotte Lindstedt-Alstermark; Kristina A. Nilsson; Bengt Ohlsson; Maria Thorstensson; Maria Boije |
| The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl)propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl)propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methyl or ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them. | ||||||
| 57 | Use of one or more metal carriers to selectively kill mammalian cells | US11472763 | 2006-06-22 | US07655620B2 | 2010-02-02 | Zoltan Kiss |
| Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death. | ||||||
| 58 | Thyroid receptor ligands | US10826100 | 2004-04-15 | US07557143B2 | 2009-07-07 | Denis E. Ryono; Jon J. Hangeland; Todd J. Friends; Tamara Dejneka; Pratik Devasthale; Yolanda V. Caringal; Minsheng Zhang; Arthur M. P. Doweyko; Johan Malm; Andrei Sanin |
| Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. | ||||||
| 59 | 4-(3,3-dihalo-allyloxy)phenoxy alkyl derivatives | US10518888 | 2003-06-27 | US07192965B2 | 2007-03-20 | Werner Zambach; Peter Renold; Arthur Steiger; Stephan Trah; Roger Graham Hall |
| Compounds of formula wherein A1, A2 and A3 are each independently of the others a bond or a C1–C6alkylene bridge; A4 is a C1–C6alkylene bridge; D is CH or N; W is, for example, O, NR7 or S; T is, for example, a bond, O, NH or NR7; Q is O, NR7, S, SO or SO2; Y is O, NR7, S, SO or SO2; X1 and X2 are each independently of the other fluorine, chlorine or bromine; R1, R2 and R3 are, for example, H, halogen, CN, nitro, C1–C6alkyl, C1–C6haloalkyl, C1–C6alkylcarbonyl or C2–C6alkenyl; R4 is, for example, H, halogen, CN, nitro or C1–C6alkyl; R5 and R6 are, for example, H, CN, OH, C1–C6alkyl, C3–C8cycloalkyl, C3–C8cycloalkyl-C1–C6alkyl, C1–C6haloalkyl, C1–C6alkoxy or C1–C6haloalkoxy; R7 is H, C1–C6alkyl, C1–C6alkoxyalkyl or C1–C6alkylcarbonyl; k, when D is nitrogen, is 1, 2 or 3; or, when D is CH, is 1, 2, 3 or 4; and m is 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds or an agrochemically acceptable salt thereof, a process for the preparation of those compositions and their use, plant propagation material treated with those compositions, and a method of controlling pests. | ||||||
| 60 | Preparation process of fluorenes | US09768621 | 2001-01-25 | US20010011144A1 | 2001-08-02 | Hiroaki Mori |
| A tetrahydrofluorene, which is represented by the following formula (I) 1 wherein R1 to R6 each independently represent a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R1 and R2 are combined together to represent nullO, nullN or nullS, R7 and R8 each independently represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group or a carboxyl group, is subjected to a hydrogen transfer reaction in the presence of a hydrogen acceptor and a catalyst, whereby a fluorene and a hydride of the hydrogen acceptor are formed at the same time. | ||||||
QQ群二维码
意见反馈
意见反馈